This proposal aims to determine if adjunctive phage therapy, used with optimal IV antibiotics, will lead to faster resolution of bloodstream infections in persistent Staphylococcus aureus bacteraemia than IV antibiotics alone.
Trial Information:
SNAP Phage Domain
Protocol Number: CT19029
Product: JIPh_Sau300 or JIPh_ Sau301
Sponsor: University of Melbourne
Sponsor Address: The Peter Doherty Institute for Infection and Immunity, University of Melbourne, 792 Elizabeth Street, Melbourne, VIC, 3000
Main Trial Contact Phone and Email: admin-sabrephi.trial@sydney.edu.au
24/7 Emergency Contact / Medical Information Phone Number: TBA
Lead Investigator: Dr Ameneh Khatami
Email: ameneh.khatami@health.nsw.gov.au
This study involves extra data collection as outlined below:
A subculture of two S. aureus isolates will be collected and sent to the Iredell Phage Lab in The Westmead Institute for Medical Research (WIMR), including any available isolate genomic data.
Up to 3 serum samples (500uL-2mL) will be collected at various timepoints
Phages infect and kill bacterial cells and do notattack human cells. They also do not affect the good bacteria in our bodies(our microbiome). For this reason, they are considered very safe.
Treatment with phages can cause side effects. You may experience none, some, or all of the side effects, which include fever, chills, headache, muscle aches, and others which can be found on the Patient Information Consent Form (PICF).
Some patients receiving phages may have changes in the levels of liver enzymes in their blood. Liver function will be monitored throughout treatment and if a big change is seen, phage treatment may be stopped or modified. Any changes to liver function tests usually get better after phage treatment is stopped.
It is possible there are side effects we do not know about. If you experience any new or unusual symptoms, tell your doctor immediately. Sometimes side effects can be serious, long lasting or permanent. If a severe side effect or reaction occurs, your doctor may need to stop the phage treatment. Your study doctor will discuss the best way of managing any side effects with you.
Data collected for the study will be stored in a secure database in accordance with the relevant Australian and state/territory privacy laws
Your information will be kept strictly confidential and only used for the study or for future research related to Staph aureus infections and related conditions.
The only people allowed to look at information that could identify you (name, address, date of birth) will be your doctors, study staff, the data management team from The University of Melbourne, and regulatory authorities who may want to check the study is carried out correctly.
Any Staph bacteria grown from your blood culture(s) will be stored in a sample bank.
Some blood samples will be sent to a lab at WIMR in New South Wales to monitor your immune response to the phage.
You may withdraw from this sub-study at any time, just notify a member of the SNAP study team at your site.
If you do withdraw, you will have the following options:
Evaluating the prevalence of vitamin C deficiency and plasma vitamin C level decay in a prospective sample of patients with Staphylococcus aureus bacteraemia enrolled in the SNAP trial
Combination Cefazolin with Ertapenem for methicillin-susceptible Staphylococcus aureus bacteremia.
A Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia
SNAPstrat: Patient stratification using SAB sub-phenotypes
Staphylococcus aureus Network: ultrasound for diagnosis of endovascular disease in Paediatrics and Youth